These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4461154)

  • 1. [Effect of toxic dose of Cytembena on the rat kidney].
    Rehulová E; Bartosová M
    Cesk Patol; 1974 Nov; 10(4):180-3. PubMed ID: 4461154
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes in the urinary tract of dogs after toxic doses of the cytostatics cyclophosphamide and Cytembena].
    Rehulová E
    Cesk Patol; 1974 Nov; 10(4):184-7. PubMed ID: 4461155
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytembena administered in combination with cyclophosphamide in Yoshida ascitic sarcoma.
    Veselá H; Jelínek V; Pujman V; Zlatkovská Z
    Neoplasma; 1971; 18(5):459-64. PubMed ID: 5119519
    [No Abstract]   [Full Text] [Related]  

  • 4. Contribution to elucidation of biochemical action mechanism of Cytembena.
    Slavíková V; Semonský M; Slavík K; Zikán V; Bloch A; Veselá H
    Neoplasma; 1971; 18(5):455-7. PubMed ID: 5119518
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cytembena and cyclophosphamide in the treatment of advanced neoplasias of the digestive tract (author's transl)].
    Matĕjková E; Rezábek K; Polák E
    Cesk Gastroenterol Vyz; 1974 Jul; 28(4):279-85. PubMed ID: 4603038
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytembena treatment of advanced gynaecological carcinomas.
    Dvorák O
    Neoplasma; 1971; 18(5):461-4. PubMed ID: 5119520
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of inflammatory rheumatic diseases using cytembena].
    Hándlová D; Vojtísek O; Králová M; Brémová A; Kanková D; Pavelka K
    Fysiatr Revmatol Vestn; 1972 Oct; 50(5):278-83. PubMed ID: 4538713
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of Cytembena in man.
    Grafnetterová J; Schück O; Smahel O; König J; Růzicková S
    Neoplasma; 1971; 18(5):447-54. PubMed ID: 5119517
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis.
    Francescato HD; Coimbra TM; Costa RS; Bianchi Mde L
    Kidney Blood Press Res; 2004; 27(3):148-58. PubMed ID: 15118361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.
    Gralla EJ; Coleman GL; Osbaldiston GW; Kashgarian M; Jonas AM
    Cancer Chemother Rep; 1975; 59(6):1071-81. PubMed ID: 816457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substances with antineoplastic effect. XL. The influence of sodium salt of beta-4-methoxybenzoyl-beta-bromacrylic acid (MBBA) and some related substances on the respiration of rat liver homogenate and Yoshida ascites rat sarcoma cells; the influence of these substances on the mechanisms of oxidative phosphorylation of the liver homogenate.
    Helia O; Jindra A; Semonský M
    Neoplasma; 1969; 16(6):597-604. PubMed ID: 5369025
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxaliplatin induced acute tubular necrosis.
    Jain A; Dubashi B; Parameswaran S; Ganesh RN
    Indian J Cancer; 2015; 52(3):363-4. PubMed ID: 26905139
    [No Abstract]   [Full Text] [Related]  

  • 13. Canine and human renal toxicity of inosine dialdehyde (NSC 118994).
    Kaufman J; Keogh B; Mittelman A; Wallens T; Murphy GP
    J Med; 1977; 8(3-4):239-51. PubMed ID: 267714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunosuppressive effect of Cytembena in rheumatoid arthritis (author's transl)].
    Truhlár P; Matl I
    Cas Lek Cesk; 1975 Jan; 114(5):150-2. PubMed ID: 1120331
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cytembena Spofa--a new antineoplastic agent].
    Semonský M; Zikán V; Veselá H
    Cesk Farm; 1973 Sep; 22(7):313-21. PubMed ID: 4582565
    [No Abstract]   [Full Text] [Related]  

  • 16. Dibromodulcitol (NSC-104800)--clinical brochure.
    Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):165-77. PubMed ID: 4989813
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of rosiglitazone on cisplatin-induced nephrotoxicity.
    Ozkaya O; Yavuz O; Can B; Dilek M; Savli E; Acikgoz Y; Bedir A; Akpolat T
    Ren Fail; 2010 Jan; 32(3):368-71. PubMed ID: 20370454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression with Cytembena: effect on antibody plaque-forming spleen cells and on hemolytic antibodies production.
    Bohunická E; Koza I; Ujházy V
    Neoplasma; 1973; 20(4):387-93. PubMed ID: 4580794
    [No Abstract]   [Full Text] [Related]  

  • 19. Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase.
    Vicente-Vicente L; Sánchez-Juanes F; García-Sánchez O; Blanco-Gozalo V; Pescador M; Sevilla MA; González-Buitrago JM; López-Hernández FJ; López-Novoa JM; Morales AI
    Toxicol Lett; 2015 Apr; 234(2):99-109. PubMed ID: 25677510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of incorporation of labelled cyclophosphamide and cytembena into human tumour.
    Jandov A ; Andrysek O; Macků F; Sámal J; Stránská E
    Neoplasma; 1973; 20(3):297-301. PubMed ID: 4725516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.